Domvanalimab is a humanized IgG1 mAb targeting TIGIT, whose combination with zimberelimab (anti-PD-1) is under investigation in a phase III trial on PD-L1-positive locally advanced or metastatic NSCLC patients. This evidence concerns the gene CD274 and non-small cell lung carcinoma.